Giovanna Armani

Prognostic value of hormone receptor expression in patients with HR+/HER2- advanced BC treated with first-line ET+CDK4/6i: results from the multicentre observational, real-world PALMARES-2 study

Francesca Ligorio, Leonardo Provenzano, Roberta Caputo, Paolo Vigneri et autres

Adjuvant chemotherapy in stage I triple-negative breast cancer: A systematic review and meta-analysis of survival outcomes

Flavia Jacobs, Alessio Polymeropoulos, Matteo De Monte, Francesca Ligorio et autres

BACKGROUND: The benefit of adjuvant chemotherapy in patients with surgically-resected, stage-I TNBC remains controversial, especially when tumors are smaller than 10 mm in maximum diameter. We conducted a meta-analysis to evaluate the impact of adjuvant chemotherapy on survival outcomes in this setting, …

it (code pays fourni par la source)

Real-world effectiveness of CDK4/6 inhibitors in older patients with HR+/HER2- advanced breast cancer: a sub-analysis of the multicenter, PALMARES-2 study

Francesca Ligorio, Leonardo Provenzano, Giuseppe Fotia, Maria Vittori Dieci et autres

BACKGROUND: Older patients with Hormone Receptor-positive, HER2-negative advanced breast cancer (HR+/HER2- aBC) are often frailer than younger patients. Endocrine therapy (ET) plus CDK4/6 inhibitors (CDK4/6i) is the standard first-line treatment regardless of age; however, CDK4/6i real-world effectiveness in older patients is unknown. …

it, us (code pays fourni par la source)

Abstract PS3-08-11: Correlation between clinical-pathological features and recurrence score from a multigene predictive assay in hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer: a real-world, retrospective, monocentric analysis of over 700 patients

G. Mazzoli, G. Fotia, M. De Santis, A. Fumagalli et autres

Abstract Background: Adjuvant cytotoxic chemotherapy followed by endocrine therapy, with or without cyclin dependent Kinase 4/6 (CDK4/6) inhibitors, significantly reduced the risk of tumor recurrence in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer (eBC) and high-risk …

it (code pays fourni par la source)

Effectiveness comparison of first-line CDK4/6 inhibitors in patients with hormone-positive HER2-negative advanced breast cancer according to tumor histology: a sub-analysis of the real-world, multicenter, Italian study PALMARES-2

Giacomo Mazzoli, Leonardo Provenzano, Maria Vittoria Dieci, Giuseppe Curigliano et autres

INTRODUCTION: Invasive lobular breast cancer (ILC) is the second most common breast cancer subtype, with distinctive biological and epidemiologic features. Although phase III trials of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in hormone receptor-positive, HER2-negative advanced breast cancer (HR+/HER2-aBC) included patients with ILC, …

it, us (code pays fourni par la source)

517P Change in breast cancer phenotype after progression to first-line CDK4/6 inhibitors

M. Bottosso, Leonardo Provenzano, A. Menichetti, Francesca Ligorio et autres

it (code pays fourni par la source)

203P Individual participant data (IPD) meta-analysis of intensified alkylating chemotherapy (IACT) in stage III, HER2-negative homologous recombination deficient (HRD) breast cancer patients

Rianne L Seefat, S. Balduzzi, Giovanna Armani, P. Schouten et autres

HRD leads to genomic instability, rendering tumors more sensitive to DNA double-strand break-inducing agents, such as alkylating agents. IACT followed by autologous stem cell transplantation, may improve outcomes in this unique, high-risk category of HRD breast cancer (BC) patients. Stage III HRD …

nl, it, gb, de (code pays fourni par la source)

Table S1-S3 from Low PD-1 Expression in Cytotoxic CD8+ Tumor-Infiltrating Lymphocytes Confers an Immune-Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value

Giulia Mazzaschi, Denise Madeddu, Angela Falco, Giovanni Bocchialini et autres

Table S1. Antibodies for Immunohistochemistry; Table S2. Magnitude of Sampling; Table S3. Magnitude of Sampling

Figure S1-S4 from Low PD-1 Expression in Cytotoxic CD8+ Tumor-Infiltrating Lymphocytes Confers an Immune-Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value

Giulia Mazzaschi, Denise Madeddu, Angela Falco, Giovanni Bocchialini et autres

Clinicopathological correlations. Figure S1: PD-L1 Expression and Clinicopathologic Parameters; Figure S2: PD-L1 Expression and TILs; Figure S3: TILs and Clinicopathological Parameters; Figure S4: NSCLC Immune Microenvironments Based on PD-L1 and TILs.

Data from Low PD-1 Expression in Cytotoxic CD8+ Tumor-Infiltrating Lymphocytes Confers an Immune-Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value

Giulia Mazzaschi, Denise Madeddu, Angela Falco, Giovanni Bocchialini et autres

Abstract Purpose: The success of immune checkpoint inhibitors strengthens the notion that tumor growth and regression are immune regulated. To determine whether distinct tissue immune microenvironments differentially affect clinical outcome in non–small cell lung cancer (NSCLC), an extended analysis of PD-L1 and …

Data from Low PD-1 Expression in Cytotoxic CD8+ Tumor-Infiltrating Lymphocytes Confers an Immune-Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value

Giulia Mazzaschi, Denise Madeddu, Angela Falco, Giovanni Bocchialini et autres

Abstract Purpose: The success of immune checkpoint inhibitors strengthens the notion that tumor growth and regression are immune regulated. To determine whether distinct tissue immune microenvironments differentially affect clinical outcome in non–small cell lung cancer (NSCLC), an extended analysis of PD-L1 and …

Table S1-S3 from Low PD-1 Expression in Cytotoxic CD8+ Tumor-Infiltrating Lymphocytes Confers an Immune-Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value

Giulia Mazzaschi, Denise Madeddu, Angela Falco, Giovanni Bocchialini et autres

Table S1. Antibodies for Immunohistochemistry; Table S2. Magnitude of Sampling; Table S3. Magnitude of Sampling